Chief Executive John Lee met with H.E. Eng. Abdullah Al-Swaha, Minister of Communications and Information Technology of Kingdom of Saudi Arabia again fol...
Agilent Technologies Inc. (NYSE: A) has announced the receipt of three 2023 Scientists’ Choice Awards; Best New Spectroscopy Product of 2022, A...
Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has o...
Maurice Michel, born 1986, receives the 20,000 euro award for his research on artificial functions of DNA repair enzymes for the treatment of Disease. Dr. ...
ADME studies are vital components of drug development, providing critical insights into the behavior of drugs within the human body. By measuring the absor...
But developing a bispecific antibody presents several challenges, including those related to dual binding, screening, pharmacodynamics, tissue tropism, and...
“This expansion of our relationship with Illumina is a continuation of Illumina Ventures’ strategy to pursue earlier stage investing,” sa...
Deloitte is proud to announce the launch of "Illustrate Change," a project that seeks to build momentum around representation in medical illustrations and ...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with canc...
The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospective, open label Phase II "basket" study to investigate CAIX expression in pat...
QIAGEN N.V. announced a notice (reiterating its notice to holders dated January 9, 2019) to holders of the following: - 0.500% Senior Unsecure...
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF, a biotechnology company focused on the researc...
This three-year collaboration aims to validate genetic drug targets and progress therapeutic molecules into clinical development. The joint resea...
Under the terms of the agreement, the two companies aim to develop multiple targeted protein degraders by combining Cullgen's proprietary uSMITE™ tar...
© 2024 Biopharma Boardroom. All Rights Reserved.
